NDC 61919-061

Lamivudine Zidovudine

Lamivudine Zidovudine

Lamivudine Zidovudine is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Direct Rx. The primary component is Lamivudine; Zidovudine.

Product ID61919-061_35e360f7-dbde-5dd9-e054-00144ff88e88
NDC61919-061
Product TypeHuman Prescription Drug
Proprietary NameLamivudine Zidovudine
Generic NameLamivudine Zidovudine
Dosage FormTablet
Route of AdministrationORAL
Marketing Start Date2015-01-01
Marketing CategoryANDA / ANDA
Application NumberANDA202418
Labeler NameDirect Rx
Substance NameLAMIVUDINE; ZIDOVUDINE
Active Ingredient Strength150 mg/1; mg/1
Pharm ClassesHepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA]
NDC Exclude FlagE
Listing Certified Through2017-12-31

Packaging

NDC 61919-061-02

2 TABLET in 1 BOTTLE (61919-061-02)
Marketing Start Date2015-01-01
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 61919-061-02 [61919006102]

Lamivudine Zidovudine TABLET
Marketing CategoryANDA
Application NumberANDA202418
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2015-01-01

Drug Details

Active Ingredients

IngredientStrength
LAMIVUDINE150 mg/1

OpenFDA Data

SPL SET ID:77eccfa0-c03c-49a3-bfa7-f31888d77161
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 200082
  • Pharmacological Class

    • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.